Comparative Pharmacology
Head-to-head clinical analysis: EDOXABAN versus HEPARIN SODIUM PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EDOXABAN versus HEPARIN SODIUM PRESERVATIVE FREE.
EDOXABAN vs HEPARIN SODIUM PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective, direct, reversible inhibitor of factor Xa, blocking the conversion of prothrombin to thrombin, thereby reducing thrombin generation and thrombus formation.
Heparin binds to antithrombin III (ATIII), causing a conformational change that accelerates the inactivation of thrombin (factor IIa) and factor Xa, as well as factors IXa, XIa, and XIIa. This inhibits clot formation and propagation.
60 mg orally once daily
Initial bolus of 80 units/kg IV, followed by continuous infusion at 18 units/kg/hour IV; adjusted to maintain aPTT of 1.5-2.5 times control.
None Documented
None Documented
Terminal elimination half-life is 10-14 hours. In patients with creatinine clearance 15-50 mL/min, half-life is prolonged to approximately 17-20 hours.
Clinical Note
moderateEdoxaban + Digoxin
"The serum concentration of Digoxin can be increased when it is combined with Edoxaban."
Clinical Note
moderateEdoxaban + Levofloxacin
"The serum concentration of Levofloxacin can be increased when it is combined with Edoxaban."
Clinical Note
moderateEdoxaban + Benzydamine
"Edoxaban may increase the anticoagulant activities of Benzydamine."
Clinical Note
moderateEdoxaban + Deferasirox
Terminal half-life is 0.5–2.5 hours (mean ~1.5 h) after IV administration; dose-dependent due to saturable clearance. At therapeutic doses, half-life averages 1–2 hours.
Renal excretion accounts for approximately 50% of the administered dose. Fecal excretion accounts for approximately 40%. Biliary excretion is minimal.
Primarily renal; small amounts in urine as unchanged drug and metabolites. Biliary/fecal elimination is negligible (<5%).
Category C
Category A/B
Anticoagulant
Anticoagulant
"The risk or severity of adverse effects can be increased when Edoxaban is combined with Deferasirox."